Vacant Post-Lung Transplant Market Is Big Opportunity For Breath Therapeutics
Where else would you find a 50% five-year mortality rate and no approved drugs? Investors are confident of the significant commercial potential for Breath Therapeutics' drug/device combo that tackles the main cause of poor mortality after lung transplantation. A €43.5m series A to finance Phase III testing has been secured.
You may also be interested in...
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.